DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for childhood apraxia of speech — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChildhood apraxia of speech maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for childhood apraxia of speech is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2002 review of treatments for acquired apraxia of speech found that most available treatments had limited data to support their use and that a particularly problematic aspect of the literature was a lack of replication of treatment findings. The review urged caution in selecting treatments and careful documentation of treatment effects because of the limited treatment database.
A 2024 review of treatment for childhood apraxia of speech reported that a wide range of treatments with varying degrees of evidence for efficacy exists. Research is beginning to emerge that compares different treatments and seeks to determine optimal treatment parameters. However, few studies to date have explored child-level predictors of treatment response, and the evidence base currently is limited in scope with respect to populations and outcomes studied. The review identified many important gaps in the literature that warrant redoubled and sustained research attention.
A 2013 cross-linguistic study described childhood apraxia of speech as a congenital neuromotor disorder characterised by deficits in the planning and execution of sequential speech movements in the absence of neuromuscular pathology. The childhood and adult forms of the disorder are not directly comparable because of differences in onset and aetiology, though they have been linked because of speech deficit similarities and a presumed similarity in impaired neural mechanisms.
What is still missing is replication of treatment findings across independent research groups, systematic investigation of which children respond to which treatments, and studies that include diverse populations and measure a broader range of outcomes. Sustained funding for comparative trials and for research that identifies child-level predictors of treatment response is needed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Seminars in Speech and Language · 2002 · 32 citations
A Summary of Treatments for Apraxia of Speech and Review of Replicated Approaches
AbstractThis article provides an overview of investigations of treatments for acquired apraxia of speech (AOS). Published treatment reports are summarized in tabular form to provide the reader with a resource for selecting and evaluating the empirical support for AOS treatments. The treatment summary highlights the fact that most available AOS treatments have limited data to support their use. A particularly problematic aspect of the AOS treatment literature is a lack of replication of treatment findings. A review is provided of the few AOS treatments for which findings have been replicated. The reader is urged to be cautious in selecting treatments and to carefully document treatment effects because of the limited treatment database.
Journal of Speech Language and Hearing Research · 2024 · 14 citations · open access
Treatment for Childhood Apraxia of Speech: Past, Present, and Future
AbstractPURPOSE: The purposes of this review article were to provide an introduction to and "bird's-eye" overview of the current evidence base for treatment of childhood apraxia of speech (CAS), identify some gaps and trends in this rapidly growing literature, and formulate some future research directions, in order to advance the evidence base and clinical practice for children with CAS. METHOD: Following a brief introduction outlining important concepts, a narrative review of the CAS treatment literature is provided, and trends and future directions are identified based on this review. The review is organized around four fundamental treatment research questions: (a) "Does Treatment X work?", (b) "Does Treatment X work better than Treatment Y?", (c) "For whom does Treatment X work?", and (d) "What does 'work' mean, anyway?" RESULTS: A wide range of CAS treatments with varying degrees of evidence for efficacy exists. Research is beginning to emerge that compares different treatments and seeks to determine optimal treatment parameters. Few studies to date have explored child-level predictors of treatment response, and the evidence base currently is limited in scope with respect to populations and outcomes studied. CONCLUSIONS: A growing evidence base supports the efficacy of a number of treatments for CAS. However, many important gaps in the literature were identified that warrant redoubled and sustained research attention. Research is beginning to emerge that addresses treatment optimization, comparison, candidacy, and outcomes. Suggestions for future research are offered, and the concept of a hypothesized pathway was applied to CAS to illustrate how components of an intervention can effect change in a clinical goal and can help guide development and refinement of treatments for children with CAS.
AbstractApraxia of speech (AOS) and childhood apraxia of speech (CAS) are acquired and congenital forms of a neuromotor disorder characterized by deficits in the planning and execution of sequential speech movements in the absence of neuromuscular pathology (McNeil, Robin, & Schmidt, 2009). The childhood and adult forms of the disorder are not directly comparable because of differences in onset and etiology. However, they have been linked because of their speech deficit similarities (Wambaugh, Duffy, McNeil, Robin, & Rogers, 2006; American Speech-Language-Hearing Association, 2007; Shuster & Wambaugh, 2008), and a presumed similarity in impaired neural mechanisms (Jacks & Robin, 2010).
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
